hGH Fragment 176-191
preclinicalAlso known as: HGH Frag 176-191
**Mechanism of Action** hGH Fragment 176-191 is a synthetic C-terminal peptide derived from human growth hormone (hGH), spanning amino acids 176–191. It is designed to mimic the lipolytic (fat-mobilizing) effects of full-length hGH without stimulating insulin-like growth factor 1 (IGF-1) secretion or significant anabolic activity. The peptide is thought to activate lipolysis by binding to growth hormone receptors in adipose tissue, triggering intracellular signaling cascades (e.g., cAMP-dependent pathways) that promote triglyceride breakdown and free fatty acid release. Its truncated structure minimizes cross-reactivity with other GH-mediated pathways, theoretically reducing risks of hyperglycemia or tissue growth. **Key Research Findings** Preclinical studies (primarily in rodent models) demonstrate that hGH Fragment 176-191 reduces adipose tissue mass and body weight without elevating IGF-1 levels or causing hyperglycemia. For example, a 2010 study in *Obesity* reported dose-dependent decreases in visceral fat and improved lipid profiles in diet-induced obese mice. However, human data remain absent; all 21 PubMed-indexed references are limited to *in vitro* or animal experiments. No pharmacokinetic or safety trials in humans have been published, and the peptide’s stability, bioavailability, and long-term effects are uncharacterized. **Clinical Relevance** Despite anecdotal use in bodybuilding and weight-loss communities, hGH Fragment 176-191 has no approved clinical indications. Its lack of human safety and efficacy data, combined with unregulated manufacturing, poses risks of contamination, dosing errors, and unknown side effects. Regulatory agencies (e.g., FDA, EMA) have not evaluated the peptide for therapeutic use. For research purposes only — not medical advice.
Key data
C80H127N23O24S2Research & studies
Peptides like BPC-157, TB-500, and GHK-Cu promote angiogenesis and extracellular matrix remodeling.; Growth hormone secretagogues (e.g., ipamorelin, CJC-1295) activate IGF-1 signaling and satellite cell repair.; Neuroactive peptides (e.g., selank, semax) enhance BDNF and HGF/c-Met pathways for neuroplasticity.; Current evidence is limited to preclinical studies, with no clinical trials available.
In silico analysis indicated that hGH fragment 176-191 peptide enhances doxorubicin binding to multiple breast cancer protein targets.; Dual-loaded chitosan nanoparticles exhibited favorable particle size, polydispersity index, and zeta potential.; Dual-loaded nanoparticles demonstrated greater anti-proliferative activity against MCF-7 cells than doxorubicin-loaded chitosan nanoparticles.
The number and diversity of performance-enhancing substances is growing due to new pharmaceuticals and black-market designer drugs.; Analytical strategies for detecting doping agents include chromatographic-mass spectrometric and alternative methods.; Substances covered include modified insulin-like growth factor-1, TB-500, selective androgen receptor modulators, and cobalt.; Detection methods must account for physicochemical properties, concentration levels, and metabolism of each compound.
Frequently asked questions
What is hGH Fragment 176-191?
**Mechanism of Action** hGH Fragment 176-191 is a synthetic C-terminal peptide derived from human growth hormone (hGH), spanning amino acids 176–191. It is designed to mimic the lipolytic (fat-mobilizing) effects of full-length hGH without stimulating insulin-like growth factor 1 (IGF-1) secretion or significant anabol
How does hGH Fragment 176-191 work?
C-terminal fragment of human growth hormone studied for lipolytic activity independent of IGF-1 signaling.
What is the research status of hGH Fragment 176-191?
hGH Fragment 176-191 is currently classified as preclinical, with 21 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of hGH Fragment 176-191?
hGH Fragment 176-191 has a molecular weight of approximately 1859.1 g/mol (formula C80H127N23O24S2).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Build on hGH Fragment 176-191 data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key